证券代码：603983 证券简称：丸美生物 公告编号：2025-010 广东丸美生物技术股份有限公司 关于2025年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号行业信 息披露：第十三号——化工》的要求，现将公司 2025 年第一季度主要经营数据 披露如下： | | | | 主要产品 | 产量（支） | 销量（支） | 营业收入（元） | | --- | --- | --- | --- | | 眼部类 | 2,659,613 | 1,468,904 | 213,971,133 | | 护肤类 | 3,383,905 | 3,607,220 | 328,758,702 | | 洁肤类 | 1,000,338 | 1,005,227 | 69,728,678 | | 美容类 | 2,480,977 | 2,821,371 | 225,779,898 | 二、2025 年第一季度公司主要产品和原材料的价格变动情况 （一）主要产品价格变 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-007 广东丸美生物技术股份有限公司 关于续聘2025年度会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 拟续聘的会计师事务所名称：华兴会计师事务所（特殊普通合伙） 一、拟聘任会计师事务所的基本情况 （一）机构信息 华兴事务所 2024 年度经审计的收入总额为 37,037.29 万元，其中审计业务 收入 35,599.98 万元，证券业务收入 19,714.90 万元。2024 年度为 91 家上市公 司提供年报审计服务，上市公司主要行业为制造业（包括计算机、通信和其他电 子设备制造业、电气机械和器材制造业、化学原料和化学制品制造业、医药制造 业、专用设备制造业等）及信息传输、软件和信息技术服务业，批发和零售业， 科学研究和技术服务业，水利、环境和公共设施管理业，房地产业，电力、热力、 燃气及水生产和供应业，交通运输、仓储和邮政业，农、林、牧、渔业等，审计 收费总额（含税）为 11,906.08 万元，其中本公司同行业上 ...

广东丸美生物技术股份有限公司 关于使用闲置自有资金委托理财的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 证券代码：603983 证券简称：丸美生物 公告编号：2025-009 委托理财受托方：大型商业银行及其他金融机构 委托理财金额：单日最高本金余额不超过 9 亿元，额度内可循环使用 委托理财产品类型：安全性高、流动性好、中低风险型的理财产品 委托理财期限：不定期 履行的审议程序：经公司董事会批准，无需提交公司股东大会审议 特别风险提示：理财产品受多种因素影响，可能存在一定的投资风险 年年度股东大会召开之日止，并提请授权管理层行使决策权并签署相关合同文件， 具体事项由公司财务部负责组织实施。 （四）风险控制 公司及子公司使用自有资金购买理财产品进行适度理财，可以提高资金使用 效率，获得一定的投资收益，为公司股东谋取更多的投资回报。 （二）资金来源 本次委托理财的资金来源为公司闲置自有资金。 （三）委托理财产品的基本情况 为进一步提高公司资金使用效益，获得一定的投资收益，为公司股东谋取更 多的投资 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-006 广东丸美生物技术股份有限公司 关于2024年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 （二）本年度使用募集资金金额及余额 公司募集资金项目本期投入募集资金 43,156,850.13 元，累计已使用募集资金 498,456,729.20 元，加上扣除手续费后累计利息收入净额 88,947,751.10 元，减除 现金管理专户余额 75,000,000.00 元，募集资金账户 2024 年 12 月 31 日余额为 305,493,021.90 元。 二、募集资金的管理情况 为了规范募集资金的管理和使用，保护投资者权益，本公司根据有关法律法规 及《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海 证券交易所上市公司自律监管指引第 1 号——规范运作》的规定，结合本公司实际 情况，制定了《广东丸美生物技术股份有限公司募集资金管理制度》（以下简称《募 集资金管理制度》）。 根据《募集资金管 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-001 广东丸美生物技术股份有限公司 关于使用闲置募集资金购买理财产品到期赎回 并继续购买的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 履行的审议程序：广东丸美生物技术股份有限公司（以下简称"公司"）第五届 董事会第二次会议通过了《关于使用部分闲置募集资金进行现金管理的议案》，同意使 用不超过人民币 20,000 万元的闲置募集资金进行现金管理，该额度可滚动使用。具体 内容详见公司于 2024 年 8 月 24 日在上海证券交易所网站披露的《关于使用部分闲置募 集资金进行现金管理的公告》（公告编号：2024-036）。 一、本次使用闲置募集资金购买理财产品到期赎回的情况 2024 年 3 月 19 日，公司向重庆银行股份有限公司两江分行（以下简称"重庆银行 两江分行"）认购了重庆银行结构性存款 2024 年第 108 期（以下简称"重庆银行结构性 存款 108 期"），认购金额为人民币 4,000 万元。上述理财产品已于 2025 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The report highlights that Marubi Biotech has received approval for the first domestic Class III medical device registration for hydroxyapatite microspheres, indicating a significant advancement in its "dual beauty integration" strategy [6][8] - The company is expected to maintain steady growth, with projected revenues of 28.92 billion, 35.90 billion, and 42.58 billion yuan for 2024, 2025, and 2026 respectively, reflecting year-on-year growth rates of 29.94%, 24.15%, and 18.60% [9] - The report emphasizes the strong market demand for hydroxyapatite products, with a compound annual growth rate of 16% in the U.S. from 2017 to 2022, outpacing other aesthetic treatments [8] Summary by Sections Investment Rating - The company maintains an "Overweight" rating, indicating a relative performance expectation of 5%-15% above the market index [12] Financial Performance - The forecasted main revenue figures are as follows: 17.32 billion yuan in 2022, 22.26 billion yuan in 2023, 28.92 billion yuan in 2024, 35.90 billion yuan in 2025, and 42.58 billion yuan in 2026 [7] - The projected net profit attributable to shareholders is expected to grow from 1.74 billion yuan in 2022 to 5.33 billion yuan in 2026, with corresponding EPS increasing from 0.43 yuan to 1.33 yuan [7][9] Market Position and Strategy - Marubi Biotech is actively expanding into the color cosmetics sector with its new brand "Lianhuo," focusing on the base makeup segment, which is expected to serve as a second growth engine [9] - The company has made strategic investments in various beauty and health-related firms, enhancing its market presence and growth potential [8][9]

评级 增持 评级变动 维持 | 交易数据 | | | --- | --- | | 当前价格（元） | 30.60 | | 52 周价格区间（元） | 20.56-36.17 | | 总市值（百万） | 12270.60 | | 流通市值（百万） | 12270.60 | | 总股本（万股） | 40100.00 | 涨跌幅比较 % 1M 3M 12M 丸美生物 -9.14 1.86 4.69 化妆品 1.31 -5.01 -0.39 -31% -11% 9% 29% 2024-02 2024-05 2024-08 2024-11 2025-02 丸美生物 化妆品 张曦月 分析师 执业证书编号:S0530522020001 zhangxiyue@hnchasing.com 2025 年 02 月 20 日 相关报告 | 1 美容护理行业 2025 年度策略：稳中求变，守 | | --- | | 正出奇 2025-01-23 | | 2 医美专题系列一：重组胶原蛋白赛道高景气延 | 续，先行者前景可期 2025-01-02 证券研究报告 公司点评 丸美生物(603983.SH) 美容护理｜ 化妆品 投资企业获批国 ...

Investment Rating - The report maintains a "Recommended" rating for the company, indicating an expected price increase of over 15% relative to the benchmark index within the next 12 months [5][11]. Core Insights - The company has made a strategic investment in Shanghai Moyang Biotechnology Co., which has received regulatory approval for its CaHA facial filler product, Aphranel®, marking a significant step in the company's "Double Beauty" strategy [1][2]. - The company is positioned as a leader in the eye care and anti-aging sectors, with strong growth anticipated from its main brand, Marubi, and its new makeup brand, Lianhuo, which is focused on the foundation segment [3][4]. - Revenue and profit forecasts show a robust growth trajectory, with expected net profits of 363 million, 470 million, and 575 million yuan for 2024, 2025, and 2026 respectively, reflecting growth rates of 39.8%, 29.7%, and 22.2% [4][8]. Summary by Sections Company Overview - Marubi has established a diversified brand matrix, with its core anti-aging brand complemented by emerging makeup and functional skincare brands [2]. Market Position - The company is actively expanding its presence in the medical aesthetics market through investments in innovative companies and technologies, enhancing its competitive edge [2][3]. Financial Projections - The company is projected to achieve total revenues of 2.93 billion, 3.65 billion, and 4.30 billion yuan for 2024, 2025, and 2026, with respective growth rates of 31.5%, 24.7%, and 17.9% [4][9]. - The earnings per share are expected to increase from 0.90 yuan in 2024 to 1.43 yuan in 2026, with corresponding price-to-earnings ratios decreasing from 33 to 21 [4][9].

Investment Rating - The report maintains a "Recommended" rating for the company, indicating an expected stock price increase of over 15% relative to the benchmark index within the next 12 months [5][11]. Core Insights - The company has made significant strides in its "Double Beauty" strategy, enhancing its growth potential through a diversified brand matrix that includes its core anti-aging brand, Marubi, alongside emerging color cosmetics and functional skincare brands [2][3]. - The approval of the CaHA facial filler product Aphranel® by the National Medical Products Administration marks a pivotal moment for the company, positioning it as a leader in the medical aesthetics sector and filling a gap in the domestic market for CaHA microsphere applications [1][2]. - The company is expected to see substantial revenue growth, with projected net profits for 2024, 2025, and 2026 estimated at 363 million, 470 million, and 575 million yuan respectively, reflecting growth rates of 39.8%, 29.7%, and 22.2% [3][4]. Summary by Sections Company Overview - Marubi Biotech has strategically invested in Shanghai Moyang Biotechnology, which specializes in the development and application of modified hydroxyapatite materials, further solidifying its position in the regenerative medicine field [1][2]. Financial Projections - The company’s revenue is projected to grow from 2,226 million yuan in 2023 to 4,304 million yuan by 2026, with a compound annual growth rate (CAGR) of approximately 28.5% to 17.9% over the forecast period [4][9]. - The expected earnings per share (EPS) are forecasted to increase from 0.65 yuan in 2023 to 1.43 yuan in 2026, indicating a strong upward trend in profitability [4][9]. Market Position - The company is recognized as a leader in the eye care and anti-aging sectors, with its main brand Marubi actively adjusting its channel and product structure to achieve stable growth [3][4]. - The emerging color cosmetics brand, Lianhuo, is expected to create a second growth curve for the company by focusing on differentiated strategies in the base makeup segment [3][4].